Meitav Investment House Ltd. Has $136,000 Stake in InMode Ltd. $INMD

Meitav Investment House Ltd. cut its stake in InMode Ltd. (NASDAQ:INMD) by 98.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,150 shares of the healthcare company’s stock after selling 910,000 shares during the quarter. Meitav Investment House Ltd.’s holdings in InMode were worth $136,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Royal Bank of Canada boosted its stake in shares of InMode by 5.7% in the 1st quarter. Royal Bank of Canada now owns 242,398 shares of the healthcare company’s stock worth $4,299,000 after buying an additional 13,032 shares during the last quarter. AQR Capital Management LLC bought a new stake in InMode during the first quarter worth $317,000. Goldman Sachs Group Inc. lifted its holdings in InMode by 234.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,123,756 shares of the healthcare company’s stock worth $19,935,000 after acquiring an additional 788,157 shares during the period. American Century Companies Inc. boosted its position in InMode by 132.9% in the second quarter. American Century Companies Inc. now owns 44,240 shares of the healthcare company’s stock worth $639,000 after purchasing an additional 25,246 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in InMode by 270.7% in the second quarter. Marshall Wace LLP now owns 555,573 shares of the healthcare company’s stock worth $8,022,000 after purchasing an additional 405,707 shares during the last quarter. Institutional investors own 68.04% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Robert W. Baird decreased their price objective on shares of InMode from $17.00 to $14.00 and set a “neutral” rating for the company in a report on Thursday, May 7th. Barclays set a $19.00 target price on shares of InMode and gave the company an “overweight” rating in a research note on Thursday, May 7th. One research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $16.00.

InMode Stock Down 0.4%

Shares of INMD opened at $14.54 on Wednesday. The business’s 50-day moving average price is $13.95 and its 200-day moving average price is $14.15. InMode Ltd. has a twelve month low of $12.72 and a twelve month high of $16.74. The stock has a market cap of $835.76 million, a PE ratio of 10.69 and a beta of 1.91.

InMode (NASDAQ:INMD) last released its quarterly earnings data on Wednesday, May 6th. The healthcare company reported $0.25 EPS for the quarter, missing analysts’ consensus estimates of $0.30 by ($0.05). The firm had revenue of $82.02 million during the quarter, compared to the consensus estimate of $79.84 million. InMode had a net margin of 23.27% and a return on equity of 13.47%. InMode’s revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.31 earnings per share.

InMode Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.